Controlled studies
Comparison groups, random assignment, and blinding can help test cause and effect. Noticeable drug effects can still make blinding difficult.
Fellowship of the Golden Grove · Learn
Research
Curiosity, grounded in evidence.
We honor the meaning people find in direct experience while asking careful questions about what science can tell us. This library brings together selected studies on psychedelics and contemplative practices, with room for both possibility and uncertainty.
These are independent publications, not Golden Grove clinical trials or measured outcomes from our members.
A moment for reflection
Where might your path begin?
Explore two short quizzes about spiritual intentions, preparation, and support. Your results suggest a learning path and a next conversation with the Fellowship.
Find your path →Read beyond the headline
Different questions need different evidence
Observational studies
Reports from everyday life can reveal useful patterns. They cannot reliably separate the effect of a substance from expectation, context, and other differences.
Personal experience
A meaningful story deserves respectful listening. It does not establish a treatment effect, a success rate, or what someone else should expect.
The research library
What the studies actually explored
Open each study’s details to see who was studied, what remains uncertain, and how we interpret its relevance. Publication dates and study types are included so promising findings can be understood in context.
Microdosing · Observational
What people report in everyday life
People who chose to microdose reported greater improvements in mood and mental-health measures than the comparison group.
Study details & limits
Who and how: 953 microdosers and 180 non-microdosing comparators · About one month.
Limits: Participants were not randomly assigned or blinded. Expectations, self-selection, and other differences between groups could contribute. Association is not proof that microdosing caused the changes.
Our reading: Useful for generating questions about real-world experience; insufficient to promise an individual result or validate a particular blend.
Microdosing · Placebo-controlled
What a small blinded mushroom study found
The study detected subjective effects but did not find reliable improvements in well-being, creativity, or cognitive performance on the measures tested.
Study details & limits
Who and how: 34 adults · Double-blind, placebo-controlled study.
Limits: The sample and observation period were small. Blinding was imperfect, and findings from one preparation and protocol cannot settle every microdosing question.
Our reading: Reported benefits deserve careful investigation rather than automatic acceptance—or dismissal. Longer, well-controlled studies remain important.
Microdosing · Self-blinding study
Why expectation belongs in the conversation
Psychological measures improved across groups. The study did not find significant between-group differences in the main accumulated outcomes, and participants’ beliefs about what they had taken mattered.
Study details & limits
Who and how: 191 participants completed a four-week self-blinding experiment.
Limits: Participants supplied their own substances and prepared their own controls, so content and blinding were less standardized than in a laboratory trial.
Our reading: Expectancy can shape experience. This study does not establish that every reported effect is imaginary, or that microdosing is an established treatment.
Supported psilocybin · Randomized trial
Depression research in a supported clinical setting
A single supported psilocybin session was associated with larger reductions in depressive symptoms than an active placebo during the study.
Study details & limits
Who and how: 104 adults with major depressive disorder · Six-week trial.
Limits: Participants were screened and received psychological support. Adverse effects occurred, follow-up was limited, and maintaining blinding is difficult when a substance has noticeable effects.
Our reading: These findings concern a specific clinical protocol. They do not establish that everyday microdosing, unsupervised use, or a retail edible treats depression.
Supported psilocybin · Randomized crossover trial
Meaning and distress in people living with cancer
Supported higher-dose sessions were associated with improvements in depression, anxiety, life meaning, and quality of life. Improvements were also reported at six-month follow-up.
Study details & limits
Who and how: 51 people with life-threatening cancer and depression or anxiety symptoms.
Limits: This was a small, specific patient group, and participants eventually received both dose conditions. Longer-term follow-up is not the same as a continuing placebo comparison.
Our reading: The research opens important questions about meaning and care; it does not predict what a particular person or product will deliver.
Breathwork · Randomized controlled study
Breathing practices and everyday mood
Breathwork, particularly an exhale-focused practice, showed greater improvement in positive mood and reduction in breathing rate than the meditation comparison.
Study details & limits
Who and how: Remote comparison of brief daily breathing practices and mindfulness meditation · One month.
Limits: The study tested specific short practices, not every technique called “breathwork.” Results do not establish treatment for a psychiatric condition or validate an intensive breathing ceremony.
Our reading: A reason to study accessible, non-substance practices with care, while recognizing that technique, health history, and context matter.
Sound meditation · Observational
Singing bowls, tension, and spiritual well-being
Participants reported less tension and several negative mood states, alongside greater spiritual well-being, after the session.
Study details & limits
Who and how: 62 participants · Before-and-after assessment of one sound-meditation session.
Limits: There was no randomized control group. Rest, group setting, expectation, and the broader experience could contribute, and lasting effects were not established.
Our reading: An encouraging early observation—not proof of disease treatment, a special healing frequency, or a guaranteed effect from a sound bath.
Hypothetical formats · An educational guide
The form is only part of the story
Capsules, tabs, honey, chocolates, gummies, teas, and powders are ways ingredients may be presented. They are not seven different kinds of evidence. The examples below are concepts for discussion, not a list of products currently available from Golden Grove.
A meaningful comparison begins with the actual ingredient, verified composition, and the preparation studied. Packaging does not turn an untested formulation into a clinically studied product.
Capsules
A capsule is a container, not an active ingredient. Whole mushroom powder, botanical material, and extracts can differ substantially. Capsule count alone does not establish identity or strength.
Tabs
“Tab” can mean a tablet, a thin film, or blotter paper. Those are different preparations. Research comparisons require a defined ingredient, measured content, and a clearly identified form.
Honey
Honey describes a food matrix. Ingredient distribution, serving consistency, storage, and testing would need evaluation before making claims about any finished preparation.
Chocolates
The number or size of pieces does not establish active content. A study of an isolated compound does not automatically validate a chocolate containing other ingredients.
Gummies
Flavor, color, and shape reveal little about contents. Research on a compound cannot establish the identity, consistency, or safety of an untested gummy.
Teas
A tea may be an infusion, an extract-based drink, or a blend of ingredients. The name alone does not establish composition or make it equivalent to material used in a trial.
Powders
Whole botanical or fungal material differs from a concentrated extract or isolated compound. A meaningful research comparison starts with verified identity and composition.
Different mushroom · Different evidence
Where Amanita fits
Amanita muscaria is different from psilocybin-containing mushrooms. Its constituents, including muscimol and ibotenic acid, do not make the psilocybin studies above evidence for an Amanita preparation.
In its food-safety review, the FDA concluded that Amanita muscaria and certain constituents do not meet its safety standard for conventional food ingredients, may be harmful, and should be avoided in foods. A capsule, tea, honey, chocolate, or gummy format does not resolve that evidence gap.
Read the FDA’s Amanita assessment ↗This section provides substance-specific context. It does not make a treatment claim or recommend an Amanita product.
Bringing understanding into everyday life
Research, reflection, and the Grove
Within the Fellowship, integration means making space to consider an experience in relation to our values, relationships, and daily choices. Community and spiritual reflection can matter without being presented as medical treatment or a guaranteed outcome.
Our Integration page describes planned weekly online meetings and in-person circles at The Green Room on Ventura. Dates and registration details will be shared there as they are arranged.
